CONMED Corporation (CNMD)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
$49.32-0.20%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · CNMD
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -39.4% |
| Our one-year growth estimate | diamond | 3.4% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 42.7 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
CNMD — debt issuance
Dated 2026-06-04
Entry into a Material Definitive Agreement. On June 3, 2026, CONMED Corporation, a Delaware corporation (“ CONMED ”), entered into separate, privately negotiated purchase agreements (the “ Purchase Agreements ”) with certain holders of its 2.25% Convertible Senior Notes due 2027 (the “ Notes ”). Under the terms of the Purchase Agreements, the Company agreed to purchase approximately $645.2 million aggregate principal amount of Notes from the holders thereof for approximately $637.2 million in…
Why it matters: Upcoming earnings will show if CONMED's revenue is steady or falling.
Worry ifQ2 2026 revenue shows growth or stabilizes compared to Q1 2026.
Less concerning ifQ2 2026 revenue declines further compared to Q1 2026.
Why it matters: Two new directors join the Board. Their experience may influence CONMED's direction.
Watch forThe Board shares a new plan influenced by the new members.
Also watch forNo new plans are shared after the new Board members join.
Why it matters: The new CFO's plans may affect CONMED's financial results and efficiency.
Watch forThe new CFO shared good financial numbers. They also talked about plans for the future.
Also watch forThere are no major changes in financial performance. No improvements have been reported.
Why it matters: A new CFO can shift financial strategies. This could affect growth and cost management.
Watch forJohn E. Gallagher outlines a clear financial strategy that supports growth.
Also watch forGallagher's strategy may cause higher costs or money problems.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$192 on $10,000 · ±1.9% | How much price usually moves either way. |
| Bad day | $432 loss on $10,000 · 4.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,136 loss on $10,000 · 41.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: John Gallagher's leadership may change financial plans and boost performance. It is important to watch his impact.
Supportive ifJohn Gallagher announced good financial results and new plans.
Worry ifAfter Gallagher was appointed, there were bad financial results and unclear plans.
Why it matters: A drop in revenue growth signals potential issues in the business or market. This could affect investor confidence.
Worry ifRevenue growth falls below the sector median of 5% year over year.
Less concerning ifRevenue growth remains above the sector median of 5% year over year.
Why it matters: New board members can bring fresh perspectives and improve governance. This can support long-term strategy.
Supportive ifCeline Martin and Jeff Mirviss take part in board decisions and committees.
Worry ifNew board members do not help much or cause governance problems.
Why it matters: Keeping this EPS guidance shows good financial health and smart cost management.
Supportive ifAdjusted EPS reported in the range of $4.30 to $4.45.
Worry ifAdjusted EPS was below $4.30.
Why it matters: Doing well in these areas can increase profits and help long-term growth.
Watch forManagement points out strong revenue growth in high-margin products.
Also watch forNo growth in high-margin product areas is reported.
Why it matters: Achieving this growth shows CONMED is on track with its 2026 goals. It reflects strong demand in key product areas.
Supportive ifQ3 organic revenue growth reported at or above 5.0%.
Worry ifQ3 organic revenue growth was below 5.0%.
Why it matters: International revenue grew 4.7% in Q1. A drop could mean bigger problems.
Worry ifInternational revenue growth is over 4.0% from last year.
Less concerning ifInternational revenue growth is under 1.0% from last year.
Why it matters: A drop in domestic sales might show bigger problems in the market.
Worry ifQ3 domestic sales show a decline worse than -8%.
Less concerning ifQ3 domestic sales stabilize or grow year over year.
Why it matters: Management maintains EPS guidance of $4.30 to $4.45. This indicates financial health.
Supportive ifManagement reaffirms EPS guidance within the $4.30 to $4.45 range.
Worry ifManagement lowers EPS guidance to less than $4.30.